Masahiro Takeuchi
Overview
Explore the profile of Masahiro Takeuchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
199
Citations
3967
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ishida H, Sunakawa Y, Kodera Y, Yoshida K, Kochi M, Kakeji Y, et al.
Eur J Cancer
. 2025 Feb;
219:115322.
PMID: 39999670
Background: As adjuvant chemotherapy for stage III gastric cancer, the phase III (JACCRO GC-07) trial showed that docetaxel plus S-1 (DS) was superior to S-1 in terms of recurrence-free and...
2.
Fujimoto A, Miyazaki K, Yakushijin K, Fujino T, Munakata W, Ejima Y, et al.
Leukemia
. 2025 Feb;
PMID: 39962328
A retrospective study of extranodal natural killer/T-cell lymphoma (ENKL) patients diagnosed between 2014 and 2021 in Japan was conducted. Among 351 patients with sufficient data, 116 (33%) were in the...
3.
Izutsu K, Ishikawa T, Shimada K, Kubo K, Kondo T, Fujimoto K, et al.
Int J Hematol
. 2025 Feb;
PMID: 39960615
Zanubrutinib is a selective second-generation Bruton tyrosine kinase inhibitor approved in various B-cell malignancies globally. The phase 1/2 BGB-3111-111 study evaluated the efficacy and safety of zanubrutinib 160 mg twice...
4.
Munakata W, Kumode T, Goto H, Fukuhara N, Shimoyama T, Takeuchi M, et al.
Br J Haematol
. 2025 Jan;
206(2):541-550.
PMID: 39778876
Zandelisib, a selective, potent PI3Kδ inhibitor, demonstrated favourable outcomes in patients with relapsed or refractory follicular lymphoma in a global phase II study. This phase II study evaluated the efficacy...
5.
Shiozawa M, Sunakawa Y, Watanabe T, Ota H, Yasui H, Yabuno T, et al.
Nat Commun
. 2024 Nov;
15(1):10217.
PMID: 39587053
The clinical significance of FOLFOXIRI (5-FU, leucovorin, oxaliplatin, and irinotecan) plus anti-EGFR monoclonal antibody using cetuximab for metastatic colorectal cancer (mCRC) remains controversial. We report results from a randomized phase...
6.
Shoji J, Goggins W, Wellen J, Cunningham P, Johnston O, Chang S, et al.
Transplantation
. 2024 Jul;
108(8):1782-1792.
PMID: 39042770
Background: Focal segmental glomerulosclerosis (FSGS) is a common cause of end-stage kidney disease and frequently recurs after kidney transplantation. Recurrent FSGS (rFSGS) is associated with poor allograft and patient outcomes....
7.
Kodera Y, Yoshida K, Kochi M, Sano T, Ichikawa W, Kakeji Y, et al.
Gastric Cancer
. 2024 Jun;
27(5):1157.
PMID: 38867085
No abstract available.
8.
Kanamori S, Takeuchi M
BMC Med Res Methodol
. 2024 Feb;
24(1):47.
PMID: 38389058
Background: Clinical trials assessing new treatment effects require a control group to compare the pure treatment effects. However, in clinical trials on regenerative medicine, rare diseases, and intractable diseases, it...
9.
Arai H, Takeuchi M, Ichikawa W, Shitara K, Sunakawa Y, Oba K, et al.
Cancer Med
. 2023 Dec;
13(1):e6818.
PMID: 38140879
Background: Individual-level surrogates are important for management in patients treated for advanced gastric cancer (AGC). This study aimed to comprehensively investigate the correlation of multiple clinical endpoints in the first-line...
10.
Nishibata T, Amino N, Tanaka-Kado R, Tsujimoto S, Kawashima T, Konagai S, et al.
Biomed Res Int
. 2023 Dec;
2023:7133726.
PMID: 38058393
The tumor microenvironment (TME) is thought to influence the antitumor efficacy of immuno-oncology agents through various products of both tumor and stromal cells. One immune-suppressive factor is prostaglandin E (PGE),...